Addressing challenges of clinical trials in acute pain: The Pain Management of Vaso-occlusive Crisis in Children and Young Adults with Sickle Cell Disease Study
- 21 March 2016
- journal article
- research article
- Published by SAGE Publications in Clinical Trials
- Vol. 13 (4) , 409-416
Abstract
Background/aims: Neuropathic pain is a known component of vaso-occlusive pain in sickle cell disease; however, drugs targeting neuropathic pain have not been studied in this population. Trials of acute pain are complicated by the need to obtain consent, to randomize participants expeditiously while optimally treating pain. We describe the challenges in designing and implementing the Pain Management of Vaso-occlusive Crisis in Children and Young Adults with Sickle Cell Disease Study (NCT01954927), a phase II, randomized, double-blind, placebo-controlled trial to determine the effect of gabapentin for vaso-occlusive crisis. Methods: In the Pain Management of Vaso-occlusive Crisis in Children and Young Adults with Sickle Cell Disease Study, we aim to assess the analgesic effect of gabapentin during vaso-occlusive crisis. Difficulties we identified included avoiding delay of notification of study staff of potential participants which we resolved by automated notification. Concern for rapid randomization and drug dispensation was addressed through careful planning with an investigational pharmacy and a single liquid formulation. We considered obtaining consent during well-visits to avoid the time constraints with acute presentations, but the large number of patients and limited duration that consent is valid made this impractical. Results: In all, 79% of caregivers/children approached have agreed to participate. The trial is currently active, and enrollment is at 45.8% of that targeted (76 of 166) and expected to continue for two more years. Maintaining staff availability after-hours remains problematic, with 8% of screened patients missed for lack of available staff. Lessons learned: Lessons learned in designing a trial to expedite procedures in the acute pain setting include (1) building study evaluations upon a standard-of-care backbone; (2) implementing a simple study design to facilitate consent and data capture; (3) assuring ample, well-trained study staff; and (4) utilizing technology to automate procedures whenever possible. Conclusion: This study design has circumvented many of the logistical barriers usually associated with acute pain trials and may serve as a prototype for future studies.Keywords
This publication has 48 references indexed in Scilit:
- A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodesHaematologica, 2013
- IMPROVE trial: A randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studiesClinical Trials, 2013
- Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)The Lancet, 2011
- Recruitment of infants with sickle cell anemia to a Phase III trial: Data from the BABY HUG studyContemporary Clinical Trials, 2010
- Experience with gabapentin for neuropathic pain in adolescents: report of five casesPediatric Anesthesia, 2005
- Neuropathic pain following multilevel surgery in children with cerebral palsy: a case series and reviewPediatric Anesthesia, 2005
- Peripheral neuropathy in pediatric systemic lupus erythematosusPediatric Neurology, 2002
- Gabapentin in Phantom Limb Pain Management in Children and Young AdultsJournal of Pain and Symptom Management, 2001
- Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell AnemiaNew England Journal of Medicine, 1995
- High-Dose Intravenous Methylprednisolone Therapy for Pain in Children and Adolescents with Sickle Cell DiseaseNew England Journal of Medicine, 1994